<DOC>
	<DOCNO>NCT01587651</DOCNO>
	<brief_summary>This Phase 4 , multicenter , open-label ( blinded Pharmacodynamic PD result ) , randomize , 3-arm , parallel-design study subject stable Coronary Artery Disease CAD . This study compare PD effect prasugrel 10 mg QD ( once-daily ) maintenance dose ticagrelor 90 mg BID ( twice daily ) maintenance dose subject stable CAD previously receive ticagrelor loading ( LD ) maintenance dose ( MD ) ..</brief_summary>
	<brief_title>Pharmacodynamic Evaluation Switching From Ticagrelor Prasugrel Subjects With Stable Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male female ; age &gt; = 18 &lt; 75 year Weight &gt; = 60 kg Receiving low dose ASA ( 75 mg 150 mg daily ) least 7 day time Visit 1 able continue regimen throughout study Stable CAD . CAD define follow : History positive stress test Previous coronary revascularization include percutaneous coronary intervention ( PCI ) , stent , coronary artery bypass graft ( CABG ) Angiographic demonstration CAD ( least 1 lesion &gt; = 50 percent ) Presence least moderate plaque compute tomography ( CT ) angiography Electron beam CT coronary artery calcification score &gt; = 100 Agatston unit If female , may enrol One follow 3 criterion meet : Had hysterectomy tubal ligation least 6 month prior sign inform consent form ( ICF ) Postmenopausal least 1 year If childbearing potential , practice 1 follow method birth control throughout study : oral , injectable , implantable hormonal contraceptive ; intrauterine device ; diaphragm plus spermicide ; female condom plus spermicide . Methods contraception acceptable partner 's use condoms partner 's vasectomy Able willing provide write informed consent enter study Have define need adenosine diphosphate ( ADP ) receptor inhibitor therapy , follow ( condition Investigator 's judgment would require therapy ) : Within = &lt; 12 month acute coronary syndrome ( ACS ) event ( unstable angina [ UA ] , nonSTelevation myocardial infarction [ NSTEMI ] , STelevation myocardial infarction [ STEMI ] ) regardless initial treatment ( , invasive versus noninvasive ) Subjects underwent angioplasty within 12 month include baremetal stent and/or drugeluting stent Had stent place unprotected leave main coronary artery last patent artery within last 12 month Received thienopyridine therapy within 30 day study entry Plan undergo coronary revascularization time trial Presence history follow : ischemic hemorrhagic stroke ; transient ischemic attack ( TIA ) ; intracranial neoplasm ; arteriovenous malformation , aneurysm ; intracranial hemorrhage ; head trauma ( within 3 month study entry ) History refractory ventricular arrhythmia increase risk bradycardic event ( eg , subject without pacemaker sick sinus syndrome , 2nd 3rd degree atrioventricular ( AV ) block bradycardicrelated syncope ) History evidence congestive heart failure ( New York Heart Association Class III = &lt; 6 month screen Severe hepatic impairment History uric acid nephropathy Uncontrolled hypertension , systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg screen Severely impaired renal function ( glomerular filtration rate &lt; 30 mL/minute ) dialysis At risk bleed Taking prohibited medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>CAD</keyword>
	<keyword>prasugrel</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>antiplatelet</keyword>
	<keyword>thienopyridine</keyword>
	<keyword>P2Y12 Inhibitors</keyword>
</DOC>